circle-image

Short

Trend Resistance

Uptrend Above: 24560

Bull Signal Above: 24700
circle-image

Term

Trend Point Acts

Trend Point: 24460

My PCR: 1.35
599 Range 1099

Bull Market Signal

circle-image

View

Trend Suport

Down Below: 24350

Bear Signal Below: 24200
Short Term View Historic Data

Nifty View Tomorrow: Friday 13 Nov 2026

Day Close

25299
Day High

25384
Day Low

25142
Day Avg

25275
12 Nov 2026
5 SMA

25123
10 SMA

24441
20 SMA

23634
50 SMA

23328
200 SMA

23989
5 EMA

25208
10 EMA

24868
20 EMA

24457
50 EMA

24304
Tomorrow
Resist 2

25540
Resist 1

25420
Mid Point

25300
Suport 1

25180
Suport 2

25060
52W High

26373
52w Low

22179
52w Down

4.07%
52w Up

14.07%
Panic View
Resist 2

25770
Resist 1

25595
Mid Point

25290
Suport 1

24990
Suport 2

24800
5d High

25424
5d Low

24388
10d High

25424
10d Low

22905
Days High & Low 20d High

25424
20d Low

22372
50d High

25424
50d Low

22179
All Avg

24193
FFTH

25079
FTTL

24239
TTTH

24584
TTTL

23567
High & Low Avg TTFH

24407
TFFL

23325
High Avg

24690
Low Avg

23710
All Avg

24200
Nifty Historic Prediction Data

Nifty Last Five Days Moves

SNo. Date Day Close Day High Day Low 5 DMA 10 DMA 20 DMA 50 DMA 200 DMA
1 12 Nov 2026 25299 25384 25142 25123 24441 23634 23328 23989
2 11 Nov 2026 25255 25424 25095 24970 24205 23500 23304 23988
3 09 Nov 2026 25044 25084 24838 24711 23949 23373 23282 23988
4 08 Nov 2026 24986 25131 24985 24464 23720 23239 23263 23991
5 06 Nov 2026 25030 25030 24388 24155 23497 23116 23248 23994
Nifty Historic Data And Moving Avg

Go Back

Innova Captab Ltd is an integrated pharmaceutical company in India with a presence across the pha...

Posted: 03 Nov 2024

Innova Captab Ltd is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Since our inception in 2006 with a small base, we have grown strength to strength and for last more than 15 years, we are catering to top Indian pharmaceuticals companies including 10 of the top 10, and 14 of the top 15. We have license to manufacture products through two state of the art manufacturing facilities while maintaining WHO-GMP, EU-GMP and other major registrations. With the support of our world class manufacturing facilities and a reliable supply value chain, we are continuously thriving to maintain highly efficient operations. The foundation of our Company is our in-house research and development (R&D). which helps to focus on to build an increasingly complex product portfolio and attract and retain customers. We proudly possess a strong team of 1000+ employees. As a responsible corporate entity, we are been continuously endeavouring to comply with Environmental, Social & Governance compliance requirements covering the aspects of Legal compliance, ethics & business conduct, quality & patient safety, human rights, labour and employment, health safety and well-being of employees, sustainability & environmental responsibility, quality management system. Our business includes CDMO business providing research, product development and manufacturing services. We were third fastest growing CDMO in terms of Operating Income over the period Fiscal 2019 to Fiscal 2023 and positioned our Company to benefit from the growth in the CDMO market by developing strong R&D and manufacturing operations for our customers to support their domestic sales and exports to certain markets. Fourteen of the top fifteen Indian pharmaceutical companies that CRISIL Research identified as the largest players in the domestic formulation market in Fiscal 2023 have been a part of our customer base. Our Capabilities World class manufacturing facilities in Baddi, Himachal Pradesh and Our manufacturing facilities have good manufacturing practices certifications in conformity with the format recommended by WHO-GMP, EU-GMP and many other international authorities. Strong R&D focus to build an increasingly complex product portfolio and attract and retain customers Our CDMO product portfolio spans across both acute and chronic therapeutic areas Leading presence and one of the fastest growing CDMOs in the Indian pharmaceutical formulations market Well established relationships with our marquee CDMO customer base Our strength in CDMO sphere includes: Our comprehensive CDMO formulation capabilities allow us to offer our customers multiple dosage forms, including oral solids, oral liquids, dry syrups and injectables, as well as more complex delivery forms such as modified and sustained release forms and tablets in capsules. We manufacture products that are in all the top ten therapeutic areas by sales in the Indian formulation market in Fiscal 2023 as identified by CRISIL Research. We manufacture products across some of the key therapeutic areas. Our operational track record in successful delivery of products, R&D, quality and technical standards and productivity Strong R&D and manufacturing operations for our customers to support their domestic sales and exports to certain markets. Our R&D laboratory is equipped with the entire suite of necessary equipment for the development of solid oral and liquid dosage forms Domestic Branded Generics Our Branded Generics business consists of the development, manufacture and distribution of generic formulation products, which are marketed and distributed in India under our own brand names through online and offline channels. Our branded generic products are generic medicines for which the patents have expired, that are sold directly to our distributors, stockists & retailers. We sell our domestic branded generic products through our pan-Indian network of distributors, stockists and pharmacies. Our generic drug products are also available online through various e-commerce pharmacy sites. We have developed a diversified branded generics product portfolio including Tablets, capsules, dry syrups, dry powder injection, ointments and liquid orals

Market Bits

"In investing, what is comfortable is rarely profitable." — Robert Arnott

Be prepared to invest in a down market and to "get out" in a soaring market, as per the philosophy of Warren Buffett.